Tag : HOMOLOGOUS RECOMBINATION DEFICIENCY

Poly (ADP-ribose)-polymerase inhibitors (PARPis) like olaparib have transformed the treatment landscape for high-grade serous ovarian cancer, with multiple trials showing significant improvement in progression-free survival (PFS). Although PFS benefits with PARPis appear to be consistent in patient